LENZ Therapeutics Future Growth
Future criteria checks 2/6
LENZ Therapeutics is forecast to grow earnings and revenue by 44.7% and 60.3% per annum respectively. EPS is expected to grow by 58.1% per annum. Return on equity is forecast to be -8.4% in 3 years.
Key information
44.7%
Earnings growth rate
58.1%
EPS growth rate
Biotechs earnings growth | 25.0% |
Revenue growth rate | 60.3% |
Future return on equity | -8.4% |
Analyst coverage | Low |
Last updated | 09 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 52 | -54 | -31 | N/A | 3 |
12/31/2025 | 13 | -79 | -63 | -61 | 2 |
12/31/2024 | N/A | -46 | -42 | -63 | 4 |
3/31/2024 | N/A | -74 | -72 | -72 | N/A |
12/31/2023 | N/A | -70 | -60 | -60 | N/A |
9/30/2023 | N/A | -56 | -47 | -47 | N/A |
12/31/2022 | 15 | -11 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LENZ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LENZ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LENZ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LENZ's revenue (60.3% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: LENZ's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LENZ is forecast to be unprofitable in 3 years.